PCN54 COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK+) NON-SMALL CELL LUNG CANCER IN UNITED STATES

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

Value in Health ◽

10.1016/j.jval.2020.08.244 ◽

2020 ◽

Vol 23 ◽

pp. S442

Author(s):

G. Gourzoulidis ◽

O. Zisimopoulou ◽

N. Boubouchairopoulou ◽

C. Michailidi ◽

C. Almond ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s223441 ◽

2019 ◽

Vol Volume 11 ◽

pp. 9195-9202 ◽

Cited By ~ 3

Author(s):

Maobai Liu ◽

Longfeng Zhang ◽

Qishu Huang ◽

Na Li ◽

Bin Zheng ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Cost-Effectiveness Of Ceritinib In The Treatment Of Previously Treated Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In The United Kingdom

Value in Health ◽

10.1016/j.jval.2015.09.1163 ◽

2015 ◽

Vol 18 (7) ◽

pp. A455-A456 ◽

Cited By ~ 5

Author(s):

Z Zhou ◽

J Zhang ◽

L Fan ◽

C Zhang ◽

J Xie

Keyword(s):

Lung Cancer ◽

United Kingdom ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

The United Kingdom ◽

Cost-Effectiveness Of Ceritinib In Previously Treated Patients With Crizotinib In Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In Canada

Value in Health ◽

10.1016/j.jval.2015.09.1199 ◽

2015 ◽

Vol 18 (7) ◽

pp. A462 ◽

Cited By ~ 1

Author(s):

Z Zhou ◽

M Hurry ◽

J Zhang ◽

L Fan ◽

C Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Previously Treated Patients ◽

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

Journal of Medical Economics ◽

10.1080/13696998.2016.1187151 ◽

2016 ◽

Vol 19 (10) ◽

pp. 936-944 ◽

Cited By ~ 8

Author(s):

Manjusha Hurry ◽

Zheng-Yi Zhou ◽

Jie Zhang ◽

Chenxue Zhang ◽

Liangyi Fan ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States

Journal of Medical Economics ◽

10.1080/13696998.2018.1443111 ◽

2018 ◽

Vol 21 (6) ◽

pp. 577-586 ◽

Cited By ~ 5

Author(s):

Zheng-Yi Zhou ◽

Alex Mutebi ◽

Simeng Han ◽

Arielle G. Bensimon ◽

Marie Louise Ricculli ◽

...

Keyword(s):

United States ◽

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

The United States ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma

PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

Value in Health ◽

10.1016/j.jval.2018.09.223 ◽

2018 ◽

Vol 21 ◽

pp. S38

Author(s):

V. Soares ◽

P. Orfanos ◽

C. Pereira

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Cost-Effectiveness Analysis of Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in Portugal

Value in Health ◽

10.1016/j.jval.2017.08.206 ◽

2017 ◽

Vol 20 (9) ◽

pp. A434

Author(s):

P Saramago ◽

M Ines ◽

F Saraiva

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Clinical Drug Investigation ◽

10.1007/s40261-019-00869-3 ◽

2019 ◽

Vol 40 (2) ◽

pp. 129-137 ◽

Cited By ~ 3

Author(s):

Qiao Liu ◽

Xia Luo ◽

Liubao Peng ◽

Lidan Yi ◽

Xiaomin Wan ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

Global & Regional Health Technology Assessment Italian Northern Europe and Spanish ◽

Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

10.1177/2284240319855072 ◽

2019 ◽

Vol 2019 ◽

pp. 228424031985507

Author(s):

Ravasio R ◽

Tiseo M ◽

Pradelli L ◽

Bellone M ◽

Gervasi A ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

First Line Treatment